NL195004B - Fenylcarbamaat bevattend farmaceutisch preparaat. - Google Patents

Fenylcarbamaat bevattend farmaceutisch preparaat.

Info

Publication number
NL195004B
NL195004B NL8800436A NL8800436A NL195004B NL 195004 B NL195004 B NL 195004B NL 8800436 A NL8800436 A NL 8800436A NL 8800436 A NL8800436 A NL 8800436A NL 195004 B NL195004 B NL 195004B
Authority
NL
Netherlands
Prior art keywords
pharmaceutical preparation
preparation containing
phenyl carbamate
containing phenyl
carbamate
Prior art date
Application number
NL8800436A
Other languages
English (en)
Other versions
NL195004C (nl
NL8800436A (nl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL195004(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NL8800436A publication Critical patent/NL8800436A/nl
Priority to NL9900033A priority Critical patent/NL195081C/nl
Publication of NL195004B publication Critical patent/NL195004B/nl
Application granted granted Critical
Publication of NL195004C publication Critical patent/NL195004C/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NL8800436A 1987-03-04 1988-02-22 Fenylcarbamaat bevattend farmaceutisch preparaat. NL195004C (nl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL9900033A NL195081C (nl) 1987-03-04 2003-05-01 Fenylcarbamaat.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04
DE3706914 1987-03-04

Publications (3)

Publication Number Publication Date
NL8800436A NL8800436A (nl) 1988-10-03
NL195004B true NL195004B (nl) 2003-07-01
NL195004C NL195004C (nl) 2003-11-04

Family

ID=6322236

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8800436A NL195004C (nl) 1987-03-04 1988-02-22 Fenylcarbamaat bevattend farmaceutisch preparaat.

Country Status (29)

Country Link
US (1) US5602176A (nl)
JP (3) JP2625478B2 (nl)
KR (1) KR0133686B1 (nl)
AT (1) AT394190B (nl)
AU (1) AU618949B2 (nl)
BE (1) BE1001467A3 (nl)
CA (1) CA1307003C (nl)
CH (1) CH675720A5 (nl)
CS (1) CS411091A3 (nl)
CY (1) CY1735A (nl)
DK (1) DK175762B1 (nl)
ES (1) ES2010527A6 (nl)
FI (1) FI89165C (nl)
FR (1) FR2611707B1 (nl)
GB (1) GB2203040C (nl)
GR (1) GR1000023B (nl)
HK (1) HK110093A (nl)
HU (1) HU201906B (nl)
IE (1) IE61714B1 (nl)
IL (1) IL85609A (nl)
IT (1) IT1219853B (nl)
LU (2) LU87150A1 (nl)
MY (1) MY103225A (nl)
NL (1) NL195004C (nl)
NZ (1) NZ223714A (nl)
PT (1) PT86875B (nl)
SA (1) SA93140384B1 (nl)
SE (1) SE8800731A0 (nl)
ZA (1) ZA881584B (nl)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
EP0755685A4 (en) * 1994-04-15 2000-05-03 Meiji Seika Kaisha PHARMACEUTICAL COMPOSITION FOR TREATING LATE DYSKINESIA
AU5620998A (en) * 1996-12-18 1998-07-15 Technion Research & Development Foundation Ltd. Phenylethylamine derivatives
EP1535902B1 (en) 1996-12-18 2007-11-07 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
ATE286725T1 (de) 1998-10-01 2005-01-15 Novartis Pharma Gmbh Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
ATE306264T1 (de) * 1998-12-11 2005-10-15 Bonnie M Davis Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen- gonadenachse
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ20023555A3 (cs) 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
KR100852834B1 (ko) * 2002-10-24 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
EP1689704A2 (en) * 2003-10-21 2006-08-16 CoLucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
GB2409453A (en) 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
EP1745180A1 (en) * 2004-04-29 2007-01-24 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
JPWO2006004201A1 (ja) * 2004-07-01 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経再生促進剤
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
KR101168211B1 (ko) * 2004-11-08 2012-07-25 엠큐어 파마슈티컬즈 리미티드 （ｓ）－３－［（１－디메틸아미노）에틸］－페닐－ｎ－에틸－ｎ－메틸－카바메이트의 제조를 위한 효과적인 방법
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
EP2111901B1 (en) 2005-09-15 2012-02-01 Sony Computer Entertainment Inc. Obtaining input for controlling execution of a game program
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
JP2009518433A (ja) * 2005-12-09 2009-05-07 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム 神経保護用の低用量ラドスチギルの使用
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
CA2661009A1 (en) * 2006-08-17 2008-02-21 Alembic Limited Improved process for the preparation of rivastigmine
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
US20100152108A1 (en) 2006-10-27 2010-06-17 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
CA2677241A1 (en) * 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
US8013181B2 (en) * 2007-04-10 2011-09-06 Dr. Reddy's Laboratories Limited Preparation of rivastigmine and its salts
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2009011901A2 (en) * 2007-07-18 2009-01-22 Colucid Pharmaceuticals, Inc. Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
EP2233465B1 (en) 2008-01-10 2017-06-28 Shanghai Institute of Pharmaceutical Industry Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
EP2349976B1 (en) 2008-08-25 2012-12-26 Jubilant Life Sciences Limited A process for producing (s)-3-[(1-dimethylamino)ethyl]phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
EP2515886B1 (de) 2009-12-22 2018-04-11 Luye Pharma AG Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
TW201618806A (zh) 2010-03-29 2016-06-01 諾華公司 有機化合物之組合物
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
DK2582799T3 (en) 2010-06-17 2018-02-12 Codexis Inc BIOCATALATORS AND PROCEDURES FOR THE SYNTHESIS OF (S) -3- (1-AMINOETHYL) -PHENOL
EA027840B1 (ru) 2010-11-15 2017-09-29 Эйджинбайо, Инк. Производные пиридазина, композиции и способы лечения когнитивного нарушения
HUE027916T2 (en) 2010-12-14 2016-11-28 Acino Ag Transdermal therapeutic system for administration of an active ingredient
CN102786441B (zh) 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
JP6017543B2 (ja) 2011-05-20 2016-11-02 エスケー ケミカルズ カンパニー, リミテッドSk Chemicals Co., Ltd. リバスティグミン含有パッチ
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
WO2013031992A1 (ja) 2011-08-31 2013-03-07 積水メディカル株式会社 貼付剤
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
ES2881081T3 (es) 2013-03-15 2021-11-26 Agenebio Inc Procedimientos y composiciones para mejorar la función cognitiva
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
CA3123897C (en) 2013-12-20 2024-02-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX2017014774A (es) 2015-05-22 2018-02-15 Agenebio Inc Composiciones farmaceuticas de levetiracetam de liberacion extendida.
CN108026107B (zh) 2015-06-19 2021-07-30 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.

Also Published As

Publication number Publication date
ES2010527A6 (es) 1989-11-16
ZA881584B (en) 1989-11-29
GB2203040C (en) 2014-07-30
IE880583L (en) 1988-09-04
FR2611707B1 (fr) 1990-04-20
IE61714B1 (en) 1994-11-30
ATA55188A (de) 1991-08-15
IT8847693A0 (it) 1988-03-04
PT86875B (pt) 1992-05-29
JPS63238054A (ja) 1988-10-04
LU90297I2 (fr) 1998-12-07
HU201906B (en) 1991-01-28
IL85609A (en) 1992-07-15
FI89165C (fi) 1993-08-25
MY103225A (en) 1993-05-29
NL195004C (nl) 2003-11-04
CS411091A3 (en) 1992-12-16
FR2611707A1 (fr) 1988-09-09
IL85609A0 (en) 1988-08-31
JPH09118617A (ja) 1997-05-06
JP2625478B2 (ja) 1997-07-02
KR880011088A (ko) 1988-10-26
HK110093A (en) 1993-10-29
CA1307003C (en) 1992-09-01
GB2203040A (en) 1988-10-12
PT86875A (pt) 1988-04-01
JPH09165362A (ja) 1997-06-24
DK112588D0 (da) 1988-03-02
KR0133686B1 (ko) 1998-04-21
NL8800436A (nl) 1988-10-03
CH675720A5 (nl) 1990-10-31
DK112588A (da) 1988-09-05
AT394190B (de) 1992-02-10
LU87150A1 (fr) 1988-11-17
BE1001467A3 (fr) 1989-11-07
DK175762B1 (da) 2005-02-14
HUT49325A (en) 1989-09-28
US5602176A (en) 1997-02-11
SE8800731L (sv) 1988-09-05
JP2859225B2 (ja) 1999-02-17
FI880972A0 (fi) 1988-03-02
GR1000023B (el) 1990-01-31
CY1735A (en) 1994-06-03
GB8804888D0 (en) 1988-03-30
SE8800731D0 (sv) 1988-03-02
AU1255488A (en) 1988-09-08
GR880100125A (en) 1989-01-31
AU618949B2 (en) 1992-01-16
NZ223714A (en) 1994-05-26
SA93140384B1 (ar) 2006-04-04
SE8800731A0 (sv) 1988-09-05
IT1219853B (it) 1990-05-24
FI880972A (fi) 1988-09-05
GB2203040B (en) 1990-10-24
FI89165B (fi) 1993-05-14

Similar Documents

Publication Publication Date Title
NL195004B (nl) Fenylcarbamaat bevattend farmaceutisch preparaat.
ATE98480T1 (de) Arzneimittelformulierungen.
DK89090D0 (da) Farmaceutisk praeparat
DK195988D0 (da) Farmaceutisk praeparat indeholdende mikrokapsler
IT8619625A0 (it) Composizioni farmaceutiche per inalazione.
DE3863963D1 (de) Pharmazeutische zusammensetzungen.
DE3868986D1 (de) Pharmazeutische zusammensetzungen.
IS3339A7 (is) Ný efnablanda lyfja
NO875419L (no) Blandinger for farmasoeytisk tape.
DK705488D0 (da) Farmaceutisk praeparat
DE3889545T2 (de) Phenylcarbonsäure-abkömmlinge.
IT8820386A0 (it) Composizioni farmaceutiche orosolubili contenti acetilcisteina.
FI872733A (fi) Farmaceutiska kompositioner.
FI872313A0 (fi) Farmaceutiska kompositioner.
FI883673A (fi) Farmaceutiska kompositioner.
NO874193D0 (no) Farmasoeytiske preparater.
FI874414A0 (fi) Kontrollerat frigoerande farmaceutiska kompositioner.
DK139388A (da) Farmaceutisk praeparat
FI875616A (fi) Farmaceutiska blandningar.
FI885828A0 (fi) Trometaminsalt av 1-metyl-b-oxo-a -(fenylkarbamoyl)-2-pyrrolpropionitril.
DK276288D0 (da) Farmaceutisk praeparat
DE3768109D1 (de) Pharmazeutische zusammensetzungen.
DK138888D0 (da) Farmaceutisk praeparat
DE3887237D1 (de) Arzneimittel.
IT8722591A0 (it) Formulazione farmaceutica contenente gemfibrozilmicroincapsulato.

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
CNR Transfer of rights (patent application after its laying open for public inspection)

Free format text: NOVARTIS AG

V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 20080222